

23 January 2023

Usage of Biologic and Biosimilar Products within Rheumatology

1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]	IV 60 & SC 169
• Adalimumab [Humira]	412
• Adalimumab Biosimilars	Amgevita 108 & Imraldi 632
• Apremilast [Otezla]	34
• Baricitinib [Olumiant]	48
• Certolizumab [Cimzia]	117
• Etanercept [Enbrel]	134
• Etanercept Biosimilars	348
• Filgotinib [Jyseleca]	<5
• Golimumab [Simponi]	104
• Guselkumab [Tremfya]	7
• Infliximab [Remicade]	51
• Infliximab Biosimilars	IV Remsima 48 & SC <5
• Ixekizumab [Taltz]	81
• Risankizumab [Skyrizi]	<5
• Rituximab [MabThera]	77
• Rituximab Biosimilars	214
• Sarilumab [Kevzara]	<5
• Secukinumab [Cosentyx]	227
• Tocilizumab [Ro Actemra]	IV 50 & SC 146
• Tofacitinib [Xeljanz]	28
• Upadacitinib [Rinvoq]	76
• Ustekinumab [Stelara]	17

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

23 January 2023

2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs?

- **Adalimumab [Humira]** <5
- **Adalimumab Biosimilars** Amgevita <5 & Imraldi <5
- **Certolizumab [Cimzia]** <5
- **Etanercept [Enbrel]** <5
- **Etanercept Biosimilars** <5
- **Golimumab [Simponi]** <5
- **Infliximab [Remicade]** <5
- **Infliximab Biosimilars** <5
- **Ixekizumab [Taltz]** <5
- **Secukinumab [Cosentyx]** <5
- **Tofacitinib [Xeljanz]** <5
- **Upadacitinib [Rinvoq]** <5

Use of <5 (less than five): Again, we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act.